CAR-cTreg infusion reversed PF without systemic inflammation characterized by diminished recruitment of fibrocytes, curtailing the production of the profibrotic cytokine IL-17a, and facilitating the remodeling of AECs, which provides a promising therapeutic strategy for the treatment of IPF. The gene discussed is IL17A; the disease is idiopathic pulmonary fibrosis.